Key result
Low to moderate doses (<300 mg/m2) of anthracyclines for childhood ALL were associated with progressive cardiac dysfunction, including diastolic dilation and decreased ejection fraction.
Why the study?
Does childhood treatment with low to moderate doses of anthracyclines (<300 mg/m2) cause late signs of cardiomyopathy in acute lymphoblastic leukemia survivors?
Cohort (n=63)
Does childhood treatment with low to moderate doses of anthracyclines (<300 mg/m2) cause late signs of cardiomyopathy in acute lymphoblastic leukemia survivors?
Even low to moderate cumulative doses of anthracyclines (<300 mg/m2) in childhood ALL survivors can lead to progressive cardiac dysfunction, underscoring the need for lifelong echocardiographic surveillance.
Authors
No takes yet. Share an insight, caveat, or question.
Associated with late dysfunction in ALL survivors; hypothesis-generating and leaves open optimal surveillance without prospective confirmation.
Rathe et al. (2007) conducted a cohort in Childhood acute lymphoblastic leukemia (n=63). Anthracycline containing therapy vs. Normal values was evaluated on Cardiac function evaluated by M-mode echocardiography and tissue doppler imaging. Low to moderate doses (<300 mg/m2) of anthracyclines for childhood ALL were associated with progressive cardiac dysfunction, including diastolic dilation and decreased ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: